TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30687799

Group type: EXPERIMENTAL
Intervention: SURgical PAtient Safety System (SURPASS) checklists combined with WHO Surgical Safety Checklist (WHO SSC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: SURPASS checklists
Number of subjects: 29
Study: 30687970

Group type: EXPERIMENTAL
Intervention: IVIG 10% (1 g/kg daily)
Number of subjects: 40
Study: 30688008

Group type: EXPERIMENTAL
Intervention: Raltegravir-based regimen (protease-inhibitor-free)
Number of subjects: 61
Study: 30688175

Group type: EXPERIMENTAL
Intervention: Expert interventions delivered via telehealth
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Education and skills related to behavioral and psychological symptoms of dementia, disease expectations, safety, activities of daily living, medical care optimization, and medication utilization
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Caregiver support interventions including respite, positive reinforcement, social and financial support, and self-care
Number of subjects: 33
Study: 30688272

Group type: EXPERIMENTAL
Intervention: Moyamoya disease
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cerebrovascular atherosclerotic disease
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 34
Study: 30688654

Group type: EXPERIMENTAL
Intervention: breathe intervention (mHealth platform)
Number of subjects: 138
Study: 30688888

Group type: EXPERIMENTAL
Intervention: Allograft adipose matrix
Number of subjects: 0
Study: 30688903

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 30689042

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day for 26 weeks (rasagiline-rasagiline group)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Rasagiline 1 mg/day for 26 weeks (placebo-rasagiline group)
Number of subjects: 198
Study: 30689105

Group type: EXPERIMENTAL
Intervention: Radiofrequency localization system (RFLS)
Number of subjects: 50
Study: 30689688

Group type: EXPERIMENTAL
Intervention: Participants without rule violations (n = 162)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Participants with rule violations (n = 158)
Number of subjects: 320
Study: 30689735

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg weekly) combined with cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3 weeks for a maximum of six cycles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (≥2400 mg) and ≥4 cycles of PF
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nimotuzumab-PF chemotherapy
Number of subjects: 35
Study: 30689759

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 7 days)
Number of subjects: 416
Study: 30689814

Group type: EXPERIMENTAL
Intervention: Nontuberculous mycobacteria isolation
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Southeast Asian origin, age 5-9 years, and severe immunodeficiency
Number of subjects: 427
Study: 30689904

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Gamma-glutamyl transferase
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Serum adiponectin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Altered liver and adipose tissue function
Number of subjects: 132
Study: 30689971

Group type: EXPERIMENTAL
Intervention: FibroScan Controlled Attenuation Parameter (CAP)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Liver Stiffness Measurement (LSM)
Number of subjects: 450
Study: 30689972

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4908

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 4908

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4908
Study: 30690141

Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon (DCB)
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty (PTA)
Number of subjects: 1980
Study: 30690254

Group type: EXPERIMENTAL
Intervention: Triple-negative breast cancer (TNBC) with positive nodal stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing tumor size and higher nodal stage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nodal stage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nodal-negative tumors (pN0)
Number of subjects: 0
Study: 30690646

Group type: EXPERIMENTAL
Intervention: MEESSI-AHF score calculation
Number of subjects: 1572
Study: 30691261

Group type: EXPERIMENTAL
Intervention: Registry data collection and analysis
Number of subjects: 134
Study: 30691339

Group type: COMPARATOR
Intervention: Prior warfarin treatment with INR <2
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Prior warfarin treatment with INR ≥2
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: No prior anticoagulation
Number of subjects: 1189
Study: 30691429

Group type: EXPERIMENTAL
Intervention: AMP
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 59
Study: 30691480

Group type: EXPERIMENTAL
Intervention: Tailored support for implementing social determinants of health documentation
Number of subjects: 30
Study: 30691536

Group type: EXPERIMENTAL
Intervention: Enadenotucirev monotherapy
Number of subjects: 61
Study: 30691827

Group type: EXPERIMENTAL
Intervention: Ductal lavage with intraductal infusion of corticosteroids and antimicrobial agents, followed by breast massage for 2 weeks.
Number of subjects: 32
Study: 30691921

Group type: EXPERIMENTAL
Intervention: Evaluation for pulmonary embolism (PE)
Number of subjects: 9091

Group type: EXPERIMENTAL
Intervention: D-dimer test
Number of subjects: 9091

Group type: EXPERIMENTAL
Intervention: Ventilation-perfusion scan
Number of subjects: 9091

Group type: EXPERIMENTAL
Intervention: CT pulmonary angiography
Number of subjects: 9091

Group type: EXPERIMENTAL
Intervention: Overall serious outcomes
Number of subjects: 9091

Group type: EXPERIMENTAL
Intervention: Nonpulmonary embolism serious condition
Number of subjects: 9091
Study: 30692121

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg daily plus palbociclib 100 mg on days 1 to 21 of each 28-day cycle
Number of subjects: 27
Study: 30692613

Group type: EXPERIMENTAL
Intervention: Late cranial ultrasound (CUS) abnormalities
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: White matter abnormality (WMA) on near-term brain MRI (ntMRI)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Bayley-III scores
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Hand function deficits
Number of subjects: 433
Study: 30693086

Group type: EXPERIMENTAL
Intervention: Real-time compression feedback using the Cardio First Angel™ (CFA) device
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard manual chest compressions
Number of subjects: 900
Study: 30693097

Group type: EXPERIMENTAL
Intervention: Psychoeducational group treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 30693284

Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback Riding (THR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30693439

Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 2400
Study: 30694208

Group type: EXPERIMENTAL
Intervention: Stay Strong + Coaching (intervention arm)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Stay Strong app (active comparator arm)
Number of subjects: 350
Study: 30694612

Group type: EXPERIMENTAL
Intervention: Urine biomarker with a minimal accepted sensitivity (MAS) of 90%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary biomarker
Number of subjects: 0
Study: 30694829

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study: 30695649

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study: 30696370

Group type: EXPERIMENTAL
Intervention: Sufficient iodine intake (188 μg/day [145-235 μg/day])
Number of subjects: 679
Study: 30696422

Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing kit
Number of subjects: 95

Group type: COMPARATOR
Intervention: Blood-based HIV self-testing kit
Number of subjects: 95

Group type: COMPARATOR
Intervention: Focus group discussions
Number of subjects: 95

Group type: COMPARATOR
Intervention: HIVST kits
Number of subjects: 95
Study: 30696435

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 17096

Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 17096
Study: 30696475

Group type: EXPERIMENTAL
Intervention: Sensorimotor/delta-ratio neurofeedback training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beta1/theta-ratio neurofeedback training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Psycho-pedagogical care
Number of subjects: 60
Study: 30696487

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 44
Study: 30696669

Group type: EXPERIMENTAL
Intervention: Assessment of asthma control during visits
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Escalation of controller therapy during visits
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Delivery of asthma action plans
Number of subjects: 884
Study: 30696950

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib + Ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone (DEX)
Number of subjects: 0
Study: 30697903

Group type: EXPERIMENTAL
Intervention: Ceritinib (second-generation ALK inhibitor)
Number of subjects: 2
Study: 30698147

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 740
Study: 30698534

Group type: EXPERIMENTAL
Intervention: T2T-based intervention programmes by speech and language therapists (SLTs)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T2T software development and testing
Number of subjects: 7
Study: 30698644

Group type: EXPERIMENTAL
Intervention: Rituximab plus lenalidomide (R2); Rituximab 375/m2 i.v. on Day 1; Lenalidomide 20 mg/day (Day 1-21 for cycle 1), 25 mg/day (Day 1-21 for subsequent cycles); followed by maintenance of lenalidomide 10 mg/day for 12 cycles.
Number of subjects: 50
Study: 30698656

Group type: EXPERIMENTAL
Intervention: Conversation task (high social demand)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Repetition task (low social demand)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Resting state data
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Task and rest context
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Striato- and thalamocortical relationships
Number of subjects: 39
Study: 30699849

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Cognitive control
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Reward learning
Number of subjects: 296
Study: 30699881

Group type: EXPERIMENTAL
Intervention: pioglitazone (15-45 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 38
Study: 30700274

Group type: EXPERIMENTAL
Intervention: HPV vaccination (at least one dose)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Nonavalent vaccine
Number of subjects: 767

Group type: COMPARATOR
Intervention: Quadrivalent vaccine
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: HPV genotype distribution
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Demographic and behavioral factors comparison
Number of subjects: 767
Study: 30700568

Group type: EXPERIMENTAL
Intervention: Olaparib 150 mg tablet twice daily combined with metronomic carboplatin AUC2 and paclitaxel 60 mg/m2
Number of subjects: 54
Study: 30700614

Group type: EXPERIMENTAL
Intervention: Postdischarge chemotherapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Postdischarge radiation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Severe acute pain
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Moderate acute pain
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Increased duration of surgery, higher pain catastrophizing score, and surgeon
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Persistent pain
Number of subjects: 124
Study: 30700726

Group type: EXPERIMENTAL
Intervention: Fresh mother's own milk once daily from enrollment until 32 weeks' corrected age
Number of subjects: 207
Study: 30701079

Group type: EXPERIMENTAL
Intervention: HIV DNA PCR testing at birth
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Xpert HIV-1 Qual
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alere q HIV-1/2 Detect
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard HIV DNA PCR testing at 6 weeks
Number of subjects: 4
Study: 30701294

Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program for discomfort reduction
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Unexposed patients
Number of subjects: 1537
Study: 30701920

Group type: EXPERIMENTAL
Intervention: ALL-2009 protocol
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: FISH technique
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: MLL/t(11q23) and c-MYC/t(8q24) gene abnormalities
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: CDKN2A/9p21 and TP53/17p13 gene deletions, quantitative and complex karyotype abnormalities
Number of subjects: 115
Study: 30702005

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30702430

Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Charity incentive
Number of subjects: 274

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Self-monitoring prompts
Number of subjects: 274

Group type: COMPARATOR
Intervention: No self-monitoring prompts
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Planning interventions
Number of subjects: 274

Group type: COMPARATOR
Intervention: No planning interventions
Number of subjects: 274
Study: 30703536

Group type: EXPERIMENTAL
Intervention: Caregiver-reported uncontrolled asthma
Number of subjects: 2

Group type: COMPARATOR
Intervention: Caregiver-reported well-controlled asthma
Number of subjects: 2
Study: 30703787

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy after high-quality cytoreductive surgery (CRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin and fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Checkmate-142 study for advanced tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCT03026140 study on neoadjuvant treatment for early tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New targeted drugs (Eltanexor and cobimetinib)
Number of subjects: 0
Study: 30704282

Group type: EXPERIMENTAL
Intervention: Personalized multiphasic coronary CT angiography
Number of subjects: 50
Study: 30704447

Group type: EXPERIMENTAL
Intervention: Push mechanisms (e.g. poor health, poor working environment, age discrimination)
Number of subjects: 15721

Group type: EXPERIMENTAL
Intervention: Stay mechanisms (e.g. attractive working conditions, good working environment)
Number of subjects: 15721

Group type: EXPERIMENTAL
Intervention: Questionnaire covering 14 domains related to labour market participation
Number of subjects: 15721
Study: 30704483

Group type: EXPERIMENTAL
Intervention: AMAP (Altered Muscle Activation Patterns)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study: 30704832

Group type: EXPERIMENTAL
Intervention: Single cycle length method for calculating EOA in AF patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single cycle length method on a postextrasystolic beat
Number of subjects: 100
Study: 30704882

Group type: EXPERIMENTAL
Intervention: HCV seropositive patients
Number of subjects: 442171

Group type: EXPERIMENTAL
Intervention: HCV-seropositive donor kidney
Number of subjects: 442171
Study: 30704966

Group type: EXPERIMENTAL
Intervention: Child-Pugh (CP) score
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: ALBI score
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Logistic model including CP or MELD
Number of subjects: 230
Study: 30705758

Group type: EXPERIMENTAL
Intervention: Radiprodil oral suspension (30 mg, 12 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional venous sampling
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mitra™ microsampling
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aqua-Cap™ Drummond microsampling
Number of subjects: 10
Study: 30706154

Group type: EXPERIMENTAL
Intervention: Bipolar disorder type II
Number of subjects: 84
Study: 30706431

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) with GI management strategies
Number of subjects: 809

Group type: COMPARATOR
Intervention: Counseling about GI events and recommendations for DMF administration
Number of subjects: 809

Group type: COMPARATOR
Intervention: Symptomatic therapies for GI AEs
Number of subjects: 809
Study: 30706490

Group type: EXPERIMENTAL
Intervention: Twice-weekly prednisolone (5 mg/kg/dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historical control cohort (HCC) - untreated boys
Number of subjects: 25
Study: 30706561

Group type: EXPERIMENTAL
Intervention: Residents with psychosis
Number of subjects: 545

Group type: COMPARATOR
Intervention: Residents with psychosis without antipsychotic medication
Number of subjects: 545
Study: 30706646

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) for 5-7 days, followed by permanent GES for 30 patients at 6 months follow-up.
Number of subjects: 43
Study: 30706753

Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for smokers with chronic pain
Number of subjects: 1093
Study: 30707098

Group type: EXPERIMENTAL
Intervention: Adapted Wii Fit balance board
Number of subjects: 58
Study: 30707510

Group type: EXPERIMENTAL
Intervention: Conditional relative weight gain
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 1 to 2 years of age
Number of subjects: 316
Study: 30708069

Group type: EXPERIMENTAL
Intervention: Clown distraction
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control distraction
Number of subjects: 59
Study: 30708264

Group type: EXPERIMENTAL
Intervention: T-DM1 (3.6 mg/kg every 3 weeks)
Number of subjects: 2002
Study: 30709364

Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of a viral vector in a Phase I gene therapy clinical trial for GAN.
Number of subjects: 0
Study: 30709417

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist consultations
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist recommendations
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Alerts regarding potentially inappropriate DOAC doses
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Alerts regarding potentially inappropriate concomitant antiplatelet agents
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Need for DOAC level monitoring
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Alerts regarding other drug related problems
Number of subjects: 585
Study: 30709431

Group type: EXPERIMENTAL
Intervention: Ublituximab (900 mg IV), Umbralisib (800 mg orally once daily), Ibrutinib (420 mg for CLL, 560 mg for NHL)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ublituximab, Umbralisib, and Ibrutinib combination
Number of subjects: 46
Study: 30710527

Group type: EXPERIMENTAL
Intervention: Treg cells incubated with rapamycin and RARA agonist (RAR568)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treg cells incubated with rapamycin alone or rapamycin with all-trans retinoic acid
Number of subjects: 0
Study: 30710573

Group type: EXPERIMENTAL
Intervention: Eucaloric diet (EBL, 50% carbohydrate, n=37)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-fat diet (FNP, 60% fat, n=25)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (CNP, 75% carbohydrate, n=24)
Number of subjects: 53
Study: 30710613

Group type: EXPERIMENTAL
Intervention: History of bullying before the age of 18
Number of subjects: 186

Group type: COMPARATOR
Intervention: No self-reported history of bullying
Number of subjects: 186
Study: 30710687

Group type: EXPERIMENTAL
Intervention: Cyclosporine/methotrexate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tacrolimus/sirolimus
Number of subjects: 200
Study: 30711626

Group type: EXPERIMENTAL
Intervention: Balloon mucosal impedance (MI) catheter system
Number of subjects: 69
Study: 30711772

Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 10 mg/week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 40 mg/week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAY 1238097 at 80 mg/week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAY 1238097 (all doses)
Number of subjects: 8
Study: 30711970

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus interferon alpha-2a (IFN)
Number of subjects: 359
Study: 30712097

Group type: EXPERIMENTAL
Intervention: 10-week individualized yoga intervention (in-person and remote via Skype)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Homework assigned between sessions
Number of subjects: 10
Study: 30713028

Group type: EXPERIMENTAL
Intervention: Plasma vitamin E levels
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: High plasma vitamin E levels with high selenium levels (median≥83.7 μg/L)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: High plasma vitamin E levels with low selenium levels (<83.7 μg/L)
Number of subjects: 229
Study: 30713498

Group type: EXPERIMENTAL
Intervention: Rituximab (initially at a low dose of 150 mg/m2)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 1

Group type: COMPARATOR
Intervention: Immunoglobulin dose escalation
Number of subjects: 1
Study: 30713538

Group type: EXPERIMENTAL
Intervention: Chimpanzee adenoviral vectors vaccine
Number of subjects: 0